Effect of the COVID-19 Pandemic on Headache in Pediatric Migraine Patients at a Single Tertiary Center

Taek Jin Lim, MD1,2, Juhyun Kong, MD1,2, Sang Ook Nam, PhD1,2, Shin Yun Byun, PhD1,2, Sungsu Jung, MD1,2, Gyu Min Yeon, MD3, Yun-Jin Lee, PhD1,2

1Department of Pediatrics, Pusan National University Children’s Hospital, Pusan National University School of Medicine, Yangsan, Korea
2Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea
3Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

Original article

Purpose: The aim of this study was to evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic on children and adolescents with migraine.

Methods: This longitudinal cohort study enrolled children and adolescents with migraine from the Department of Pediatric Neurology at our hospital from January 2017 to June 2021. Self-reported data from individual headache diaries were used. The patients were questioned about their headache frequency and intensity, stress, physical activity, changes in mood and sleep, and their school and home lives during the COVID-19 pandemic. The Pediatric Migraine Disability Assessment (Ped-MIDAS) scoring system was applied to assess headache-related disability.

Results: In total, 325 pediatric migraine patients (mean age 12.8±5.6 years, 62.5% female) were included in this study. The average monthly frequency of migraine headaches was 2.17±1.32 and 4.62±3.29 before and during the COVID-19 pandemic (P<0.001), respectively. The Ped-MIDAS score was obtained for 207 patients both before and during the pandemic, and the total score slightly increased from 13.8 to 14.7 points (P=0.295). Sixty patients (18.5%) showed significantly worsening migraine headaches. Younger age (P=0.017), mood deterioration (P<0.001), sleep problems (P<0.001), increased acute medication use (P=0.010), and larger changes in the Ped-MIDAS score (P=0.002) were significantly associated with worsening headache in the logistic regression analysis.

Conclusion: Headache attacks in children and adolescents with migraine were more frequent during the COVID-19 pandemic than before it. Worsening headaches could be independently attributed to younger age, mood deterioration, and poor sleep during the COVID-19 pandemic.

Keywords: Migraine disorders; Headache; COVID-19; Child; Adolescent

Introduction

Since coronavirus disease 2019 (COVID-19) was declared a global pandemic on March 11, 2020 by the World Health Organization, the COVID-19 pandemic has affected over 373 million people worldwide, of whom approximately 5,678,000 have died and around 295,000,000 have recovered, resulting in significant economic damage [1]. Evidence exists documenting the effects of the...
COVID-19 pandemic on the psychological and physical welfare of the general population [2]. An online survey of 3,637 COVID-19-free persons from China during the COVID-19 pandemic described increases in the prevalence of insomnia, anxiety, and depressive symptoms [3].

Migraine is one of the most common neurological diseases, for which a genetic predisposition plays a critical role along with internal and external sources of environmental influence, including psychosocial and psycho-emotional challenges, hormonal dysregulation, and dietary factors, among others [4]. Migraine attacks are considered to result from natural fluctuations in neuronal excitability and trigger factors [5]. Stress and post-stress rest are known migraine triggers [6]; Moreover, migraine is associated with various psychiatric comorbidities [7]. For migraine patients, the outbreak of COVID-19 has also had some notable impacts, including negative therapeutic effects and psychological distress [8]. Pediatric migraine is among the most common primary or comorbid neurological disorders in children, with a prevalence ranging from 3% in preschool children to 23% in adolescents [9]. A nationwide survey found that the prevalence of headache among school children was 29.1% in South Korea [10]. Migraine headaches were reported by 8.7% of children (7.0% of boys, 10.3% of girls), tension headaches by 13.7% (10.7% of boys, 16.3% of girls), and others by 6.7%. Pediatric patients with migraine are especially vulnerable to stressful and anxious encounters [4]. Thus, these patients constitute a specific at-risk population that should be monitored for COVID-19-related effects on their headache evolution.

Remarkable negative effects on hospital-based headache care have been reported during the COVID-19 pandemic in studies from Denmark and Norway [11]. A recent study conducted in Italy reported that, during the COVID-19 quarantine, subjects with migraine had fewer migraine attacks and less pain, as well as moderate levels of depression [12]. Although prior studies observed that migraine attack patterns during the COVID-19 pandemic possibly differed from the pre-pandemic patterns [8,12], very limited data have been published on the frequency or severity of migraine attacks in children during the COVID-19 pandemic, except for a cross-sectional study that surveyed migraine frequency [13].

The purpose of this retrospective longitudinal cohort study in children and adolescents with migraine was to compare the frequency and severity of migraine attacks before and during the COVID-19 pandemic, and to identify the potential risk factors for worsening migraine attacks during the pandemic.

Materials and Methods

1. Patient enrollment

We conducted a retrospective longitudinal cohort study involving children and adolescents with migraine between January 2017 and September 2021 at a pediatric neurology clinic affiliated with Pusan National University Children’s Hospital. The inclusion criteria were as follows: (1) age from 6 to 19 years; (2) fully completed headache survey and questionnaire investigating the effect of the COVID-19 pandemic on headache and quality of life; (3) the availability of neuroimaging data to rule out secondary headache with or without significant risk factors; and (4) patients who had been treated for migraine at least 6 months before the COVID-19 pandemic, and who were followed-up with headache diaries and the Pediatric Migraine Disability Assessment (Ped-MIDAS) score for at least 5 months since April 2020. The diagnosis of migraine as a primary headache was made by pediatric headache specialists according to the International Classification of Headache Disorders, third edition [14]. Patients were classified as having migraine with or without aura, chronic migraine, probable migraine, or episodic syndromes associated with migraine. The exclusion criteria were as follows: (1) patients with other types of primary headache; (2) patients with organic brain disease other than migraine; (3) patients with cognitive impairment; (4) administration of other chronic medications for ≥ 2 months; and (5) patients being treated or previously treated for COVID-19.

2. Clinical evaluation for headache and headache-related disability

Based on medical records and headache diaries, the following information was obtained: duration and frequency of headaches, detailed headache features, accompanying symptoms (nausea/vomiting, dizziness, photophobia, phonophobia, osmophobia, and allodynia), lifestyle factors (sleep cycle, physical activity, school or study work, mood, and stressful situation), and acute and preventive medications for migraine. The questionnaire used in this study is shown in Appendix 1. Patients were asked about the effect of the COVID-19 pandemic on their headaches and quality of life. Patients’ attention and concern about COVID-19 and worsening headaches during the COVID-19 pandemic were evaluated. Significantly worsening headache was defined as occurring if patients described that they had experienced an increase in headache frequency of more than 50% or headache intensity stronger by more than 2 points on average according to the Wong–Baker pain rating scale, compared to their habitual migraine headaches. The total Ped-MIDAS score [15] was used to compare the degree of disabil-
ity experienced in daily life related to the severity of headache during the 3 months before and after the first declaration of the COVID-19 pandemic in April 2020. The severity of headache was divided into four grades according to the total Ped-MIDAS score (I: little or no disability, 0–5; II: mild disability, 6–10; III: moderate disability, 11–20; IV: severe disability, ≥ 21). Changes in mood and sleep quality during the COVID-19 pandemic were measured using the 7-point Patient’s Global Impression of Change (PGIC) scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; 7, very much worse) [16]. The primary outcomes investigated were as follows: (1) the change in the Ped-MIDAS score during the COVID-19 pandemic, and (2) the predictive risk factors related to aggravation of the Ped-MIDAS score or worsening headache, including sleep, daily activities, mood, and accompanying symptoms.

3. Standard protocol approvals, registrations, and patient consent
This study received ethical approval (number: 05-2022-043) from the Institutional Review Board of Pusan National University Yangsan Hospital. Written informed consent was obtained from each participant and his or her parents or guardians.

4. Statistical analysis
Statistical analyses were performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA) using raw scores. To compare patients with and without worsening headache, the two-tailed chi-square or Fisher exact test was used for the analysis of categorical data, and the independent t-test was used for continuous variables with normal distributions. The Mann–Whitney test was used for continuous variables with non-normal distributions. In addition to univariate non-parametric statistical tests, the results of the paired and independent t-tests were confirmed using the Wilcoxon signed-rank test and the Mann–Whitney test. Multiple stepwise linear regression was performed to detect the clinical variables that were predictive of changes in the Ped-MIDAS score before and during the COVID-19 pandemic. Multivariate logistic regression was used to identify independent risk factors related to worsening headaches during the COVID-19 pandemic. Odds ratios with 95% confidence intervals were used to test differences within groups. In all analyses, P values < 0.05 were considered to indicate statistical significance. GraphPad Prism for Mac V.8.43 (GraphPad Software, San Diego, CA, USA) was used to generate the figures.

Results
1. Characteristics of migraine patients during the COVID-19 pandemic
Among the 417 initially recruited children and adolescents with migraine, 373 completed the questionnaires and 325 (122 boys and 203 girls) were finally enrolled in this study; 48 patients who were not followed up during the COVID-19 pandemic were excluded (Fig. 1). The mean age of the 325 patients was 12.8 ± 5.6 years (range, 8 to 19), and migraine without aura accounted for the majority (55.1%, 179/325) (Table 1). Nausea/vomiting was the

![Fig. 1. Flowchart of patient enrollment in the study. Of the 417 children and adolescents with migraine, 373 completed the questionnaire, and 48 patients who were not followed up during the coronavirus disease 2019 (COVID-19) pandemic were excluded. Finally, 325 patients were enrolled in this study.](https://doi.org/10.26815/acn.2022.00038)

| Table 1. Demographics and clinical characteristics of pediatric migraine patients |
|-----------------------------------------------|
| Characteristic                                | Value         |
| Total patients                                | 325           |
| Boys/Girls                                    | 122/203 (37.5/62.5) |
| Age (yr)                                      | 12.8 ± 5.6 (8–19) |
| Diagnosis                                     |               |
| Migraine without aura                         | 179 (55.1)    |
| Migraine with aura                            | 36 (11.1)     |
| Chronic migraine                              | 40 (12.3)     |
| Probable migraine                             | 60 (18.4)     |
| Cyclic vomiting syndrome                      | 10 (3.1)      |
| Accompanying symptoms                         |               |
| Nausea/vomiting                               | 231 (71.1)    |
| Dizziness                                     | 190 (58.5)    |
| Photophobia                                   | 204 (62.8)    |
| Phonophobia                                   | 171 (52.6)    |
| Osmophobia                                    | 153 (47.1)    |
| Allodynia                                     | 23 (7.1)      |
| Medication                                    |               |
| Acute                                         | 316 (97.2)    |
| Preventive                                    | 193 (59.4)    |

Values are presented as number (%) or mean±standard deviation (range).
most common accompanying symptom (71.1%), followed by photophobia (62.8%), dizziness (58.5%), phonophobia (52.6%), and osmophobia (47.1%). Acute and preventive treatments for migraine were performed in 97.2% and 59.4% of patients, respectively.

The results of the questionnaire on the effects of COVID-19 on patients’ headaches and overall life are summarized in Table 2. The average monthly frequency of migraine headache was 2.17 ± 1.32 before and 4.62 ± 3.29 during the COVID-19 pandemic (P < 0.001). Stress increased in 197 (60.6%) patients, and 251 (77.2%) patients reported a decrease in their physical activity. More than 80% of patients reported medium (n = 129, 39.7%) to strong (n = 145, 44.6%) concerns about COVID-19. The PGIC scores of mood and sleep quality using slightly deteriorated to 4.9 and 4.6 points, respectively. In total, 33.8% of subjects reported increases in acute treatment, and 18.8% described additions to or changes in preventive medication.

2. Changes in and determinants of the Ped-MIDAS score
The Ped-MIDAS was administered to 207 patients both before and during the COVID-19 pandemic, and the total score rose slightly from 13.8 (pre-COVID-19) to 14.7 (post-COVID-19) points, but the difference was not statistically significant (P = 0.295) (Fig. 2). Multiple regression analysis revealed that younger age (P = 0.039), mood deterioration (P < 0.001), sleep disturbance (P = 0.018), increased acute medication (P = 0.011), and worsening headache (P = 0.017) were important clinical factors associated with the aggravation of Ped-MIDAS scores during the COVID-19 pandemic (Table 3).

3. Characteristics and risk factors of significantly worsening headache
Sixty (18.5%) of the 325 patients showed significantly worsening migraine headache (Table 4). Patients with worsening headache had significantly higher stress (78.3% vs. 56.6%, P = 0.041), were more likely to have strong concerns about COVID-19 (60.0% vs. 41.1%, P = 0.032), and their mood (6.1 ± 1.4 vs. 4.1 ± 0.9, P < 0.001) and sleep (5.8 ± 1.2 vs. 4.0 ± 0.9, P < 0.001) scores were worse than those without worsening headache. An increase in

Table 2. Effects of the COVID-19 pandemic on clinical characteristics and medications

| Migraine patients (n=325) | Value |
|--------------------------|-------|
| Headache frequency (day/month) | P<0.001* |
| Before COVID-19 | 2.17 ± 1.32 |
| During COVID-19 | 4.62 ± 3.29 |
| Stress | |
| Decreased | 15 (4.6) |
| Unchanged | 113 (34.8) |
| Increased | 197 (60.6) |
| Physical activity | |
| Decreased | 251 (77.2) |
| Unchanged | 65 (20.0) |
| Increased | 9 (2.8) |
| Interest in COVID-19 | |
| None | 15 (4.6) |
| Little | 32 (9.8) |
| Moderate | 113 (34.8) |
| Strong | 165 (50.8) |
| Concerns about COVID-19 | |
| None | 3 (0.9) |
| Minor | 48 (14.8) |
| Moderate | 129 (39.7) |
| Strong | 145 (44.6) |
| PGIC scale (range, 1–7) | |
| Mood | 4.9 ± 1.1 |
| Sleep | 4.6 ± 1.2 |
| Problems of hospital access | 45 (13.8) |
| Acute treatment | |
| Decreased | 24 (7.4) |
| Unchanged | 191 (58.8) |
| Increased | 110 (33.8) |
| Addition or change in preventive treatment | 61 (18.8) |

Values are presented as mean ± standard deviation or number (%).
COVID-19, coronavirus disease 2019; PGIC, Patient’s Global Impression of Change.

*P<0.001, before vs. during the COVID-19 pandemic.

Fig. 2. Changes in total Pediatric Migraine Disability Assessment (Ped–MIDAS) scores before and during the coronavirus disease 2019 (COVID-19) pandemic. The total Ped–MIDAS scores (13.8±6.3 vs. 14.7±7.8, P=0.295) were not significantly different before and during the COVID-19 pandemic (MIDAS; the number of patients who completed the Ped–MIDAS both before and during the COVID-19 pandemic=207/325, 63.7%).
Table 3. Results of multiple regression analyses of increased changes in the total Ped-MIDAS score before and during the COVID-19 pandemic

| Variable                        | Estimate | Sed. Error | P-value |
|---------------------------------|----------|------------|---------|
| Age                             | -0.025   | 0.432      | 0.039a  |
| Stress, increased               | 0.134    | 0.434      | 0.147   |
| Concerns about COVID-19         | 0.097    | 0.176      | 0.253   |
| Mood worsening (PGIC 6–7)       | 0.874    | 0.207      | <0.001a |
| Sleep worsening (PGIC 6–7)      | 0.352    | 0.033      | 0.018a  |
| Acute treatment, increased      | 0.581    | 0.049      | 0.011   |
| Preventive treatment, added/changed | 0.173   | 0.458      | 0.082   |
| Worsening headache              | 1.173    | 0.271      | 0.017   |

Ped–MIDAS, Pediatric Migraine Disability Assessment; COVID–19, coronavirus disease 2019; Sed., standard error of difference; PGIC, Patient’s Global Impression of Change.

*aP<0.05.

Table 4. Comparison of characteristics between patients with and without significantly worsening migraine headache during the COVID–19 pandemic

| Characteristic                  | No worsening headache | Worsening headache | P-value |
|---------------------------------|-----------------------|--------------------|---------|
| Number of patients              | 265                   | 60                 |         |
| Age (yr)                        | 14.6±4.5              | 10.4±6.7           | 0.038a  |
| Diagnosis                       |                       |                    |         |
| Migraine without aura           | 147 (55.5)            | 32 (53.3)          | 0.173   |
| Migraine with aura              | 29 (10.9)             | 7 (11.7)           | 0.071   |
| Chronic migraine                | 33 (12.5)             | 7 (11.7)           | 0.065   |
| Probable migraine               | 50 (18.9)             | 10 (16.7)          | 0.218   |
| Cyclic vomiting syndrome        | 6 (2.3)               | 4 (6.7)            | 0.061   |
| Stress, increased               | 150 (56.6)            | 47 (78.3)          | 0.041   |
| Physical activity, decreased    | 201 (75.8)            | 50 (83.3)          | 0.175   |
| Concerns about COVID–19         |                       |                    |         |
| Not at all                      | 3 (1.1)               | 0                  |         |
| Little                          | 42 (15.8)             | 6 (10.0)           |         |
| Moderate                        | 111 (41.9)            | 18 (30.0)          |         |
| Strong                          | 109 (41.1)            | 36 (60.0)          |         |
| PGIC scale (range, 1–7)         |                       |                    |         |
| Mood                            | 4.1±0.9               | 6.1±1.4            | <0.001a |
| Sleep                           | 4.0±0.9               | 5.8±1.2            | <0.001a |
| Problems with hospital access   | 37 (14.0)             | 8 (13.3)           | 0.384   |
| Acute treatment, increased      | 73 (27.5)             | 37 (61.7)          | <0.001a |
| Preventive treatment, added/changed | 43 (16.2)    | 18 (30.0)          | 0.025a  |
| ΔPed–MIDAS score                | 0.5±0.2               | 1.9±3.4            | <0.001a |

Values are presented as mean±standard deviation or number (%).

Table 5. Logistic regression analysis for independent clinical variables related to worsening migraine headache during the COVID–19 pandemic

| Variables                        | Estimate | P-value | OR (95% CI) |
|----------------------------------|----------|---------|-------------|
| Age                              | -0.037   | 0.017a  | 0.975 (0.955–0.996) |
| Stress, increased                | 0.231    | 1.121   | 2.127 (0.420–5.783) |
| Concerns about COVID–19          | 0.345    | 0.087   | 1.057 (0.291–4.155) |
| Mood worsening (PGIC 6–7)        | 0.874    | <0.001a | 2.797 (1.743–5.295) |
| Sleep worsening (PGIC 6–7)       | 0.352    | <0.001a | 4.121 (1.061–6.903) |
| Acute treatment, increased       | 0.574    | 0.010a  | 1.761 (1.271–2.456) |
| Preventive treatment, added/changed | 0.201   | 0.102   | 1.887 (0.886–4.481) |
| ΔPed–MIDAS score                 | 0.679    | 0.002a  | 1.905 (1.057–2.135) |

COVID–19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; PGIC, Patient’s Global Impression of Change; Ped–MIDAS, Pediatric Migraine Disability Assessment; ΔPed–MIDAS, the longitudinal change in scores before (pre) and during (post) the COVID–19 pandemic (post–COVID–19 Ped–MIDAS minus pre–COVID–19 Ped–MIDAS).

*aP<0.05.
Psychological stressors are generally recognized as potential triggers of recurring episodes of pediatric migraine. Stressful and emotionally overwhelming experiences in schools and/or families can contribute to hypersensitivity of the central nervous system, increasing the risk of pediatric migraine attacks [19,20]. Previous studies have reported that adverse life events and stressful events are significantly associated with headache frequency [21,22]. COVID-19 itself is a major social stressful event, and it is already known that a positive correlation exists between major life stress and headache frequency [21]. In our study, we found that 60.6% of patients with pediatric migraines reported increased stress, and patients with worsening headache during the COVID-19 pandemic were more likely to show increased stress than those who did not.

Our study indicated that poor sleep was an independent risk factor for worsening headache and increased Ped-MIDAS scores during the COVID-19 pandemic. Two possibilities can be considered to explain the results based on prior research. First, Schuh-Hofer et al. [23] revealed that migraineurs mobilized 5-hydroxytryptamine from intracellular stores early in a migraine attack. It is noteworthy that 5-hydroxytryptamine plays a diverse role in a variety of human behaviors, including sleep, mood, and pain, and it could promote wakefulness and have a negative effect on sleep [24]. Therefore, poor sleep may be a manifestation of pathways that also lead to frequent migraine attacks. Second, poor sleep may also lower pain thresholds [25]. Previous studies have reported that the relationship between poor sleep and migraine is a series of bidirectional interactions [24]. Fortunately, poor sleep can be modified through medical advice and personal efforts. Therefore, we suggest that it is essential that pediatric neurologists consider evaluating patients’ sleep condition in order to improve their daily life during the COVID-19 period.

Mood disorders are well documented as comorbidities of migraine in children and adolescents [26,27]. Additionally, worsening of migraine attacks was only observed in patients who reported higher anxiety during the COVID-19 lockdown [28]. Anxiety is psychosocial and affective factor involved in pediatric migraine onset and chronicity [26], and similar mechanisms have been theorized to underpin both anxiety and chronic pain [29]. Therefore, children with migraine should be considered as a specific vulnerable population that needs specialized and multi-professional attention during and after the epidemic, as well as during major stressful events.

This study had several limitations. First, this was a retrospective study. Patients were asked to evaluate their condition and fill out questionnaires for the periods 3 to 4 months before and after the declaration of the pandemic. Therefore, this study may have been affected by the recall bias of patients’ self-reports. Second, the as-
Assessment of the Ped-MIDAS scores before and during the pandemic was completed in 63.7% of all patients. Third, healthy controls were not included in the study because we focused on changes in clinical symptoms in patients with migraine. Fourth, the PGIC scale was not specifically designed to evaluate mood or sleep changes. Specific anxiety or depression test results for patients with deteriorated mood scores were not included in this study. Fifth, we did not investigate patients’ stress, physical activity, mood, and sleep conditions separately before and during the COVID-19 pandemic; instead, we only asked them to describe their changes. Since this study was conducted for 5 months to 1.5 years after the COVID-19 pandemic was declared, the effect of changes in patients’ age is thought to be insignificant. Disability of daily life due to headache was compared before and during COVID-19 using Ped-MIDAS scores. Finally, restrictions on school and social activities and the closure of public facilities occurred unexpectedly, and the long-term effects of mental and physical health problems, weight gain, wearing a mask, and changes in lifestyle could not be evaluated.

In conclusion, our results identified that some children and adolescents with migraine during the COVID-19 pandemic suffered from worsening migraine attacks. In addition, several potential risk factors contributing to worsening headache were identified, and it is hoped that the identification of these factors will help manage pediatric migraine patients during the COVID-19 pandemic. We suggested that proactive monitoring of mood swings and sleep disturbance during the COVID-19 pandemic in younger children with migraine can contribute to early identification of the exacerbation of headaches. Future research can be strengthened by adding evaluations that quantify various clinical variables and by expanding the number of patients.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Taek Jin Lim, https://orcid.org/0000-0002-1817-5138
Yun-Jin Lee, https://orcid.org/0000-0003-4727-7018

Author contribution

Conceptualization: TJL, JK, SON, and YJL. Data curation: TJL, JK, SYB, SJ, and GMY. Formal analysis: SJ and GMY. Methodology: SON, SJ, and YJL. Project administration: TJL and JK. Writing—original draft: TJL, JK, and SYB. Writing—review & editing: SON, SJ, and YJL.

Acknowledgements

We would like to thank Editage (www.editage.co.kr) for English language editing.

References

1. Haghdoost F, Carcel C, Chandrasekhar D, Rodgers A, Delcourt C. The impact of coronavirus disease 2019 (COVID-19) pandemic on migraine disorder. J Neurol 2021;268:4429-35.
2. Zhong BL, Luo W, Li HM, Zhang QQ, Liu XG, Li WT, et al. Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey. Int J Biol Sci 2020;16:1745-52.
3. Li Y, Qin Q, Sun Q, Sanford LD, Vgontzas AN, Tang X. Insomnia and psychological reactions during the COVID-19 outbreak in China. J Clin Sleep Med 2020;16:1417-8.
4. Guidetti V, Faedda N, Siniatchkin M. Migraine in childhood: biobehavioural or psychosomatic disorder? J Headache Pain 2016;17:82.
5. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol 2015;14:65-80.
6. Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep 2018;22:81.
7. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016;87:741-9.
8. Ma M, Fang J, Li C, Bao J, Zhang Y, Chen N, et al. The status and high risk factors of severe psychological distress in migraine patients during nCOV-2019 outbreak in Southwest China: a cross-sectional study. J Headache Pain 2020;21:100.
9. Genizi J, Khouriieh Matar A, Zelnik N, Schertz M, Srugo I. Frequency of pediatric migraine with aura in a clinic-based sample. Headache 2016;56:113-7.
10. Rho YI, Chung HJ, Lee KH, Eun BL, Eun SH, Nam SO, et al. Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey. Headache 2012;52:592-9.
11. Kristoffersen ES, Faiz KW, Sandset EC, Storstein AM, Stefansen S, Winsvold BS, et al. Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway. J Headache Pain 2020;21:128.
12. Parodi IC, Poeta MG, Assini A, Schirinzì E, Del Sette P. Impact of quarantine due to COVID infection on migraine: a survey in Genova, Italy. Neurol Sci 2020;41:2025-7.
13. Al-Hashel JY, Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain 2020;21:115.
14. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.
15. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999;53:988-94.
16. Guy W. Clinical global impressions (CGI) scale, modified. In: Rush AJ, editor. Handbook of psychiatric measures. Washington DC: American Psychiatric Association; 2000. p. 100-2.
17. Verhagen IE, van Casteren DS, de Vries Lentsch S, Terwindt GM. Effect of lockdown during COVID-19 on migraine: a longitudinal cohort study. Cephalalgia 2021;41:865-70.
18. Suzuki K, Takeshima T, Igarashi H, Imai N, Danno D, Yamamoto T, et al. Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study. J Headache Pain 2021;22:53.
19. Balottin U, Chiappelli M, Rossi M, Termine C, Nappi G. Childhood and adolescent migraine: a neuropsychiatric disorder? Med Hypotheses 2011;76:778-81.
20. Connelly M, Bickel J. An electronic daily diary process study of stress and health behavior triggers of primary headaches in children. J Pediatr Psychol 2011;36:852-62.
Appendix 1. Questionnaire for the change of headache and life style during the COVID-19

Age: (y), Birth date:

Sex: □ Male □ Female

• Do you have any other illnesses besides migraine?
  □ Yes □ No (disease name: )

• Habits
  (1) Do you drink any caffeinated beverages (coffee, tea, Japanese tea, etc.)?
    □ No
    □ Yes. Drink ( ) cups per day

  (2) Do you drink alcoholic beverages?
    □ Never
    □ < 1 day/week
    □ 1-2 days/week
    □ 3-5 days/week
    □ 6-7 days/week

  (3) Do you smoke?
    □ Not at all.
    □ I used to smoke.
    □ I currently smoke.

• Effects of COVID-19 on work or school activity
  Choose one of the following three and the relevant content.

  (1) Student/ Kindergarten student.
    □ Constant school (school)
    □ Irregular school (school)
    □ Suspension of school (school)
    □ Other ( )

  (2) Continuing to work on the front line in case of an emergency.
    □ Medical service related work □ Store staff
    □ Shipping work □ Other ( )

  (3) After declaring a state of emergency, he refrained from going out and is working from home.
    □ Housekeeper □ Office worker □ Public official
    □ Faculty member □ Service industry □ Other ( )

  (4) Other jobs ( )

• Do you have an interest in COVID-19?
  □ 1 None □ 2 Very little □ 3 Little □ 4 Moderate □ 5 Strong
Do you have any concerns about COVID-19 (including any kind of anxiety or worry related to COVID-19)?

□ 1 None □ 2 Very little □ 3 Little □ 4 Moderate □ 5 Strong

※ Please answer the questions below by comparing the situation after COVID-19.

• Compared to your usual migraine headache, is the frequency or intensity worse?
  □ Yes □ No
  If yes, answer the following (1) through (6) questions (if your headache has worsened).

(1) Frequency:
Before COVID-19: Average monthly ( ) days → After: Average monthly ( ) days

(2) Strength (between 1-10 points)
Before COVID-19: Average ( ) point → After: Average ( ) point

(3) The duration when you have a headache.
Before COVID-19: Average ( ) minutes/( ) hours/( ) days
  → After: Average ( ) minutes/( ) hours/( ) days

• After the COVID-19, did you have any problems visiting medical facilities (hospitals)?
  □ Yes □ No

• Have you ever run out of medicine because of a problem visiting the hospital?
  □ Yes □ No

• Is your stress different from before?
  □ Decrease □ Unchanging □ Increase

• Is your physical activity different from before?
  □ Decrease □ Unchanging □ Increase

• Has the frequency of acute drugs used for headache attacks changed?
  □ Decrease □ Unchanging □ Increase

• Has the migraine prevention/maintenance drug (daily medication) been added or changed?
  □ Yes □ No

• Check one of the following 7 levels after COVID-19, compared to before COVID-19.
  1 point: Much better.
  2 points: Much better.
  3 points: Very little better.
  4 points: Same as before.
  5 points: It’s getting a little bad.
  6 points: It’s getting worse.
  7 points: Very much worse.
  (1) How strong is your headache? Dot.
  (2) How are you feeling these days? Dot.
  (3) How’s your sleep condition? Dot.